IP Library Granted Patent US 8,765,712
Granted Patent B2
US 8,765,712 · App. 13/144,613 · Granted Jul 1, 2014

Agent for preventing and treating pityriasis versicolor

Inventor: Peter Mayser (Biebertal, DE)
Assignee: Justus-Liebig-Universitaet Giessen
A61K31/15A61K31/17A61K31/195
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,712
App. No.
13/144,613
Granted
Jul 1, 2014
Kind
B2
Abstract

The present invention concerns an agent for prevention and treatment of pityriasis. The agent according to the present invention comprises at least one transaminase inhibitor effectively inhibiting the transamination process which is of pathogenetic relevance for the disease, prevents a recurrence of the disease and which protects the human skin flora. Upon release into the environment, no resistances are induced in other fungi.

Claims (9)

1. A method for treatment of pityriasis versicolor (pityriasis) comprising topically administering to a subject suffering therefrom an effective amount of an agent comprising at least one transaminase inhibitor that suppresses tryptophan-dependent pigment synthesis of Malassezia yeasts.

2. The method according to claim 1 , characterized in that the transaminase inhibitor specifically inhibits transaminase TAM 1.

3. The method according to claim 1 , characterized in that the transaminase inhibitor is aminooxyacetate.

4. The method according to claim 1 , characterized in that the transaminase inhibitor is canaline, carboxymethoxylamine, cycloserine, tunicamycin and/or a monoamine oxidase (MAO) inhibitor.

5. The method according to claim 1 , characterized in that the transaminase inhibitor is terizidone.

6. The method according to claim 1 , characterized in that the transaminase inhibitor is a non-convertible substrate of TAM 1.

7. The method according to claim 1 wherein the agent is formulated in a shaking mixture, suspension cutanea aquosa, aqueous, oily, or alcoholic solution, as emulsion, paste, cream, ointment, spray, lipophilic gel, hydrophilic gel, plaster, shampoo, bath additive or mud.

8. The method according to claim 1 , characterized in that the transaminase inhibitor is contained in a concentration of 0.05-5% w/w.

9. The method of claim 6 wherein the non-convertible substrate of TAM 1 is selected from the group consisting of nitrotryptophan, phenelzine, 6-mercaptopurine monohydrate, 6-thioguanine, D-galactosamine hydrochloride, and 2-(hydroxyethyl)urea.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Apr 2, 2024
From: NOVIGO GMBH & CO. KG; NOVIGO GMBH
To: NOVIGO GMBH
Reel/Frame 066986/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2018
From: JUSTUS-LIEBIG UNIVERSITAT GIESSEN
To: NOVIGO GMBH & CO. KG
Reel/Frame 045053/0124 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2011
From: MAYSER, PETER
To: JUSTUS-LIEBIG UNIVERSITAT GIESSEN
Reel/Frame 027294/0968 →
Priority Claims (2)
DE 10 2009 004 959 · Jan 14, 2009 · national
DE 10 2009 035 114 · Jul 29, 2009 · national
Continuity (1)
Related Publication 20120129800A1 · May 24, 2012